DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
10.11
+1.06 (11.71%)
At close: Nov 3, 2026, 4:00 PM EST
9.90
-0.21 (-2.08%)
Pre-market: Nov 4, 2026, 4:04 AM EST
DBV Technologies Revenue
DBV Technologies had revenue of $1.60M in the quarter ending September 30, 2026, a decrease of -42.86%. This brings the company's total for the last twelve months to $3.84M, down -31.63% year-over-year. In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth.
Revenue (ttm)
$3.84M
Revenue Growth
-31.63%
P/S Ratio
168.22
Revenue / Employee
$21,976
Employees
170
Market Cap
628.48M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Geron | 204.56M |
| Zevra Therapeutics | 136.07M |
| Iambic Therapeutics | 18.25M |
| Adlai Nortye Group | 18.06M |
| Crescent Biopharma | 11.88M |
| Aclaris Therapeutics | 8.22M |
| Entera Bio | 42.00K |
DBVT News
- 1 day ago - DBV Technologies to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 4 days ago - DBV Technologies price target lowered to $46 from $51 at Guggenheim - TheFly
- 5 days ago - DBV sinks after warning cash not sufficient to fund operations - TheFly
- 6 days ago - DBV Technologies price target lowered to $47 from $55 at Citizens - TheFly
- 6 days ago - DBV Technologies Report Wider Q3 Loss, Advances Peanut Allergy Patch Toward Potential Launch - Nasdaq
- 6 days ago - DBV Technologies (DBVT) Q3 2026 Earnings Call Transcript - The Motley Fool
- 6 days ago - What DBV Technologies (DBVT) Said on Its Q3 Earnings Call - MarketBeat
- 6 days ago - DBV Technologies reports Q3 EPS (14c), consensus (15c) - TheFly